Inhalation Anesthesia Market Expect $3.42 Bn By 2032, CAGR: 9.2%

Inhalation Anesthesia Market Size Worth $3.42 Billion By 2032 | CAGR: 9.2%

The global inhalation anesthesia market size is expected to reach USD 3.42 billion by 2032, according to a new study by Polaris Market Research. The report “Inhalation Anesthesia Market Share, Size, Trends, Industry Analysis Report, By Drug (Sevoflurane, Desflurane, Isoflurane, Others); By Application; By End-Use; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The rising prevalence of minimally invasive surgeries, driven by their effectiveness in reducing hospitalization durations, contributes to market growth. These procedures are known to reduce post-operative pain, resulting in less reliance on painkillers with lower dosage requirements for patients.

Furthermore, because fewer cuts or stitches are required, the hospitalization duration is comparatively shorter, and patients are not required to return to the hospital on a regular basis. According to Becker's Spine Review data, over 160 Ambulatory Surgical Centers (ASCs) in the United States are performing minimally invasive spine surgeries as of December 2020, representing a significant increase over the last decade.

The increase in emergency and trauma cases, combined with patients' increasing preference for ambulatory day care procedures, will have a positive impact on the expansion of the inhalation anesthesia market.

The rising prevalence of diseases such as cardiac disease, neurovascular disease, and other chronic conditions will increase the demand for a wide range of surgical interventions. According to the Centers for Disease Control and Prevention, over 730,000 Americans have a heart attack each year, highlighting the growing demand for medical procedures.

The market for inhalation anesthetics faces challenges such as lower adoption rates in specific surgical procedures, widespread generic competition for nearly all halogenated agents, and recent patent expirations, which hamper on market growth.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below:

Anesthesia machine manufacturers have focused on incorporating features such as electronic vaporizers, advanced monitoring capabilities, and ergonomic designs to improve patient safety and overall workflow in healthcare settings. Furthermore, there has been a growing emphasis on the development of inhalation anesthetics with improved pharmacokinetic profiles and lower environmental impact. The market has witnessed a growing partnership between pharmaceutical companies and healthcare providers to streamline anesthesia management protocols and ensure optimal patient outcomes.

Inhalation Anesthesia Market Report Highlights

  • In 2023, the sevoflurane segment accounted for the largest revenue share in the inhalation anesthesia market, because of its therapeutic properties, sevoflurane is a commonly used anesthetic. It is an inhalation anesthetic in the ether class with a non-irritating aroma, low pungency, and a low blood gas partition coefficient.
  • The hospital segment accounted for the highest market share during the forecast period, owing to the increasing demand for numerous surgical procedures due to the supportive reimbursement policies for the surgeries being performed in the hospital.
  • In 2023, North America accounted for the largest market share in the inhalation anesthesia market, owing to the increasing prevalence of chronic diseases due to unhealthy dietary habit and sedentary lifestyle changes will facilitate the market’s growth.
  • Asia Pacific region witnessed for the fastest growth in the inhalation anesthesia market due to the surging awareness regarding to the health issue and the increasing expenditure on healthcare in the region. Existence of a large number of patients who choose various surgical interventions will drive the market’s growth in the region.
  • The global key market players include AbbVie Inc., Baxter International Inc., Dechra Pharmaceuticals PLC (Halocarbon Life Sciences LLC), Fresenius Kabi AG (Fresenius SE & Co. KGaA), Hikma Pharmaceuticals PLC, Jiangsu Hengrui Medicine Co. Ltd, Lunan Pharmaceutical Group Co. Ltd, Merck KGaA, Piramal Enterprises Limited, and Troikaa Pharmaceuticals Ltd.

Polaris Market Research has segmented the inhalation anesthesia market report based on drug, application, end-use, and region:

Inhalation Anesthesia, Drug Outlook (Revenue - USD Billion, 2019 - 2032)

  • Sevoflurane
  • Desflurane
  • Isoflurane
  • Others

    Inhalation Anesthesia, Application Outlook (Revenue - USD Billion, 2019 - 2032)

  • Induction
  • Maintenance

Inhalation Anesthesia, End-Use Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospitals
  • Ambulatory Surgical Centers
  • Others

Inhalation Anesthesia, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Inhalation Anesthesia Market Report Scope

Report Attributes


Market size value in 2024

USD 1.69 billion

Revenue forecast in 2032

USD 3.42 billion


9.2% from 2024 – 2032

Base year


Historical data

2019 – 2022

Forecast period

2024 – 2032

Quantitative units

Revenue in USD billion and CAGR from 2024 to 2032

Segments Covered

By Drug, By Application, By End-Use, By Region

Regional scope

North America, Europe, Asia Pacific, Latin America; Middle East & Africa


Report customization as per your requirements with respect to countries, region and segmentation

For Specific Research Requirements

Request for Customized Report